Kestra Medical Technologies (NASDAQ:KMTS) Announces Quarterly Earnings Results

Kestra Medical Technologies (NASDAQ:KMTS) issued its quarterly earnings data on Monday. The company reported ($1.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.61), RTT News reports. During the same period in the previous year, the business posted ($1.18) EPS. Kestra Medical Technologies updated its FY 2025 guidance to EPS.

Kestra Medical Technologies Trading Down 1.9 %

KMTS opened at $23.83 on Tuesday. Kestra Medical Technologies has a twelve month low of $20.00 and a twelve month high of $26.06.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. Wells Fargo & Company began coverage on shares of Kestra Medical Technologies in a report on Monday, March 31st. They set an “overweight” rating and a $28.00 target price on the stock. The Goldman Sachs Group began coverage on Kestra Medical Technologies in a report on Monday, March 31st. They set a “neutral” rating and a $24.00 target price on the stock. Bank of America started coverage on shares of Kestra Medical Technologies in a research note on Monday, March 31st. They set a “buy” rating and a $30.00 target price for the company. Stifel Nicolaus initiated coverage on shares of Kestra Medical Technologies in a research note on Monday, March 31st. They set a “buy” rating and a $28.00 price objective for the company. Finally, Piper Sandler began coverage on Kestra Medical Technologies in a research note on Monday, March 31st. They issued an “overweight” rating and a $27.00 price objective for the company. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $27.67.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.